Physician profile
Jennifer Chen
NPI 1619321304
$11,428.19
in general payments reported to CMS, 2019-2025
37 companies · $2,892 in 2025
The $2,892 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $363 · 2021: $777 · 2022: $1,794 · 2023: $1,689 · 2024: $3,770 · 2025: $2,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,015 · Consulting Fee: $225 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,015.36 |
| Consulting Fee | $225.00 |
| Education | $109.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,766.17 | 2020-2025 | Tavneos, Evenity, Krystexxa |
| Gilead Sciences, INC. | $1,397.53 | 2020-2025 | Vemlidy, Yeztugo |
| Glaxosmithkline, LLC. | $1,089.10 | 2019-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| E.R. Squibb & Sons, L.L.C. | $882.77 | 2020-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $737.34 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $695.11 | 2020-2025 | Lokelma, Breztri, Fasenra |
| Scilex Pharmaceuticals INC. | $398.91 | 2022-2025 | Ztlido |
| Lilly USA, LLC | $332.40 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $299.53 | 2022-2025 | |
| Travere Therapeutics, INC. | $274.76 | 2024 | |
| Viiv Healthcare Company | $272.90 | 2022-2024 | Apretude |
| Horizon Therapeutics Plc | $271.02 | 2022-2023 | Krystexxa |
| Dynavax Technologies Corporation | $245.70 | 2020-2025 | Heplisav-B |
| Edwards Lifesciences Corporation | $233.39 | 2024-2025 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $222.63 | 2023-2025 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $211.62 | 2020-2025 | |
| Insmed, INC. | $177.44 | 2025 | Arikayce |
| Agios Pharmaceuticals, INC. | $174.24 | 2024-2025 | Pyrukynd |
| Stryker Corporation | $173.45 | 2024 | Omnicurve |
| Astellas Pharma US INC | $162.98 | 2024-2025 | Veozah |
| Viatris Specialty LLC | $155.39 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $153.96 | 2020-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Cequr Corporation | $148.28 | 2023 | Cequr Simplicity |
| Janssen Biotech, INC. | $147.14 | 2025 | Carvykti, Rybrevant |
| Teva Pharmaceuticals USA, INC. | $136.90 | 2024 | Austedo Xr |
| Lexicon Pharmaceuticals, INC. | $113.96 | 2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $100.67 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.98 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $77.18 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $69.71 | 2025 | |
| Kaleo, INC. | $63.60 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $42.35 | 2025 | Rexulti |
| Dexcom, INC. | $41.53 | 2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $24.90 | 2025 | |
| Daiichi Sankyo INC. | $19.37 | 2019 | |
| Modernatx, INC. | $16.98 | 2025 | Mresvia |
| Cranial Technologies, INC | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.